Can you discuss study design, rationale, results, and implications of recent trials focused on anti-TNF biosimilars in the setting of RA, AS, and related conditions?

Can you discuss study design, rationale, results, and implications of recent trials focused on anti-TNF biosimilars in the setting of RA, AS, and related conditions?

Can you discuss and explain the study design, rationale, results, and clinical implications of the most recent clinical evidence — i.e. clinical trials — focused on the safety and efficacy of approved biosimilar therapies, such as INFLIXIMAB-DYYB (INFLECTRA®) RA; with a focus on anti-TNF biosimilars in the setting of RA, AS, and related conditions?

CLICK HERE FOR CME CREDIT

Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Leonard Calabrese, DO

Leonard Calabrese, DO

Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Vice Chairman Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute